comparemela.com

Latest Breaking News On - Real life data - Page 1 : comparemela.com

Amolyt Pharma Announces Abstracts Accepted for Presentation at the GRS Congress, ECE and ENDO

Amolyt Pharma Announces Abstracts Accepted for Presentation at the GRS Congress, ECE and ENDO
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

TNF-Inhibitor Biosimilars Prove Effective, Safe in Pediatric Non-infectious Uveitis

Real-life data reveal the effectiveness of TNF-inhibitor biosimilars in minimizing ocular flares and preserving visual acuity in pediatric patients with uveitis.

Transcripts for BBCNEWS BBC News 20211011 08:20:00

dr mary ross davie is the uk director for professional midwifery at the royal college of midwives. thank you for talking to us. tell us some of the reasons why unvaccinated sorry, pregnant women are not getting the covid jab. it is getting the covid ab. it is understandable, getting the covid jab. it 3 understandable, when people are pregnant, they want to think really carefully about what they put in their bodies and this was a new vaccine and we know that young working men in particular have been really targeted by anti fax messages, miss and it is understandable that there had been some concern that is really important that people seek out good evidence based information to make their informed decisions anti vaxx messages. speak to your midwife and obstetrician, go to our websites and look at the information there because what we re seeing now really clear real life data, really

Investegate |Acarix AB Announcements | Acarix AB: Positive preliminary data from Acarix s exploratory heart failure study SEISMO

Positive preliminary data from Acarix’s exploratory heart failure study SEISMO Acarix AB (publ) today announced positive preliminary data from the exploratory SEISMO study, using its modified CADScor ®System on a potential heart failure application. The SEISMO trial was initiated in June 2018 to evaluate the possibility of developing an algorithm that can differentiate patients referred with suspicion of heart failure. The study, with in total 199 patients at two sites in Denmark, included the last patient in 2020. Completing the inclusion to the exploratory heart failure study was a great milestone for all involved. The new data looks promising for early heart failure rule out and will be important for all affected patients today waiting all too long for a final diagnosis. The data could warrant a follow-up study to consolidate findings and bring more data for algorithm development,” said Professor Peter Søgaard, MD and primary investigator.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.